RECURSION PHARMACEUTICALS, INC. (RXRX)
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Recursion Pharmaceuticals, Inc.
No splits on record
Nothing in RXRX's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $74.68M | $58.84M | $43.88M | $39.68M | $10M | $3.41M | $1.71M |
| YoY Growth | 26.9% | 34.1% | 10.6% | 296.8% | 193.0% | 99.5% | - |
| Cost of Revenue | $120.95M | $45.24M | $42.59M | $48.27M | $0 | $0 | $45.81M |
| Gross Profit | -$46.27M | $13.6M | $1.29M | -$8.59M | $10M | $3.41M | -$44.1M |
| Gross Margin | -62.0% | 23.1% | 2.9% | -21.7% | 100.0% | 100.0% | -2577.3% |
| Research and Development | $425.27M | $314.42M | $241.23M | $155.7M | $135.27M | $63.32M | $45.81M |
| Selling, General, and Administrative | $176.59M | $178.18M | $110.82M | $81.6M | $57.68M | $25.26M | $18.95M |
| Other | $0 | $0 | -$699K | -$162K | -$178K | -$549K | -$608K |
| Total Operating Expenses | $601.86M | $492.61M | $351.35M | $237.13M | $192.78M | $88.03M | $64.15M |
| Operating Income (EBIT) | -$648.13M | -$479M | -$350.06M | -$245.73M | -$182.78M | -$84.61M | -$62.44M |
| Operating Margin | -867.9% | -814.1% | -797.8% | -619.3% | -1827.8% | -2479.2% | -3649.4% |
| Interest Expense | $1.81M | $1.57M | $97K | $55K | $2.95M | $1.36M | $635K |
| Interest Income | $22.79M | $15.76M | $19.12M | $6.25M | $73K | $336K | $1.74M |
| Other Income (Expense) | $3.24M | $14.22M | $17.93M | $6.25M | -$3.7M | -$2.39M | $562K |
| Income Before Tax (EBT) | -$644.89M | -$464.79M | -$332.13M | -$239.48M | -$186.48M | -$87.01M | -$61.88M |
| Income Tax Expense | -$136K | -$1.13M | -$4.06M | $0 | $0 | $0 | $0 |
| Net Income | -$644.76M | -$463.66M | -$328.07M | -$239.48M | -$186.48M | -$87.01M | -$62.52M |
| Net Income Margin | -863.4% | -788.0% | -747.7% | -603.5% | -1864.8% | -2549.3% | -3654.3% |
| Supplementary Data | |||||||
| EPS | -1.44 | -1.69 | -1.58 | -1.36 | -1.05 | -0.52 | -0.37 |
| Diluted EPS | -1.44 | -1.69 | -1.58 | -1.36 | -1.05 | -0.52 | -0.37 |
| Weighted Average OS | 447.45M | 274.21M | 207.85M | 175.54M | 170.27M | 165.79M | 165.79M |
| EBITDA | -$559.38M | -$426.72M | -$307.63M | -$227.66M | -$175.12M | -$81.7M | -$59.39M |
| EBITDA Margin | -749.0% | -725.2% | -701.1% | -573.7% | -1751.2% | -2393.9% | -3471.1% |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $743.29M | $594.35M | $391.56M | $549.91M | $285.12M | $262.13M | $69.88M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $231.45M | $0 | $0 |
| Cash and Short-Term Investments | $743.29M | $594.35M | $391.56M | $549.91M | $516.56M | $262.13M | $69.88M |
| Accounts Receivable | $24.65M | $49.17M | $3.09M | $2.75M | $9.09M | $156K | $151K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $33.16M | $70.75M | $43.48M | $17.15M | $9.07M | $4.16M | $6.36M |
| Total Current Assets | $812.85M | $714.27M | $438.14M | $569.81M | $534.72M | $266.44M | $76.4M |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $169.48M | $233.21M | $120.17M | $121.45M | $64.72M | $25.97M | $24.37M |
| Goodwill | $162.16M | $148.87M | $52.06M | $801K | $801K | $801K | $0 |
| Intangible Assets | $309.9M | $335.86M | $36.44M | $1.31M | $1.39M | $1.69M | $0 |
| Long-Term Investments | $0 | $5.63M | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $957K | $1.93M | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $18.79M | $8.82M | $6.89M | $7.92M | $8.72M | $3.69M | $663K |
| Total Long-Term Assets | $661.28M | $734.33M | $215.56M | $131.47M | $75.63M | $32.15M | $25.03M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $1.47B | $1.45B | $653.7M | $701.29M | $610.35M | $298.58M | $101.43M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $18.12M | $21.61M | $3.95M | $4.59M | $2.82M | $1.07M | $1.26M |
| Short-Term Debt | $9.09M | $8.43M | $41K | $97K | $90K | $1.07M | $77K |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $278K | $292K |
| Current Unearned Revenue | $37.6M | $61.77M | $36.43M | $56.73M | $10M | $10M | $0 |
| Other Current Liabilities | $31.77M | $50.85M | $23.75M | $20.43M | $11.74M | $3.08M | $1.7M |
| Total Current Liabilities | $147.71M | $187.47M | $93.17M | $100.27M | $46.66M | $23.1M | $6.68M |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $9.56M | $19.02M | $1.1M | $536K | $633K | $11.41M | $12.42M |
| Long-Term Unearned Revenue | $114.01M | $118.77M | $51.24M | $70.26M | $6.67M | $16.67M | $0 |
| Long-Term Deferred Tax Liabilities | $23.25M | $16.57M | $1.34M | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $2.08M | $4.73M | $0 | $0 | $4.11M | $450.99M | $203.39M |
| Total Long-Term Liabilities | $195.56M | $226.34M | $97.09M | $115.22M | $20.75M | $481.77M | $219.01M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $343.26M | $413.82M | $190.26M | $215.48M | $67.41M | $504.87M | $225.7M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $5K | $4K | $2K | $2K | $2K | $0 | $0 |
| Retained Earnings | -$2.08B | -$1.43B | -$967.62M | -$639.56M | -$400.08M | -$213.6M | -$126.59M |
| Comprehensive Income & Other | $36.72M | -$7.64M | $0 | $0 | -$126K | $0 | $0 |
| Other Stockholders' Equity | $3.21B | $2.47B | $1.43B | $1.13B | $943.02M | $7.31M | $2.33M |
| Total Equity | $1.13B | $1.03B | $463.44M | $485.81M | $542.94M | -$206.29M | -$124.27M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $1.47B | $1.45B | $653.7M | $701.29M | $610.35M | $298.58M | $101.43M |
| Supplementary Data | |||||||
| Total Debt | $77.97M | $108.49M | $50.67M | $51.01M | $11.48M | $15.66M | $16.17M |
| Net Debt | -$665.33M | -$485.86M | -$340.89M | -$498.91M | -$273.64M | -$246.46M | -$53.71M |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$644.76M | -$463.66M | -$328.07M | -$239.48M | -$186.48M | -$87.01M | -$61.88M |
| Depreciation & Amortization | $83.7M | $36.49M | $24.4M | $11.76M | $8.4M | $3.94M | $2.49M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $827K | $0 | $0 |
| Stock-Based Compensation | $111.22M | $81.69M | $53.5M | $27.91M | $14.84M | $4.29M | $1.39M |
| Changes in Working Capital: | |||||||
| Accounts Receivable | $32.94M | -$6.07M | -$7.76M | -$2K | $114K | -$1.12M | $605K |
| Inventory | $0 | $0 | $0 | $0 | $7.83M | $0 | $0 |
| Accounts Payable | -$2.62M | $6.43M | -$987K | $1.77M | $1.75M | -$185K | -$340K |
| Other Working Capital | -$16.64M | -$38.37M | -$35.51M | $103.16M | -$10M | $32.14M | $143K |
| Total Working Capital Change | $13.69M | -$38M | -$44.26M | $104.92M | -$306K | $30.83M | $408K |
| Other Non-Cash Items | $64.34M | $24.31M | $6.64M | $11.37M | $4.1M | $2.54M | $555K |
| Net Cash from Operating | -$371.81M | -$359.17M | -$287.78M | -$83.52M | -$158.61M | -$45.4M | -$57.04M |
| Investing Activities | |||||||
| Capital Expenditures | -$6.47M | -$13.7M | -$11.96M | -$37.06M | -$39.8M | -$5.83M | -$3.91M |
| Acquisitions | $0 | $277.1M | $1.84M | $0 | $231.95M | -$2.6M | $0 |
| Purchases of Investments | -$3.81M | $0 | $0 | $0 | -$301.14M | $0 | $0 |
| Sales of Investments | $0 | $0 | $480K | $230.61M | $69.19M | $0 | $0 |
| Other Investing Activities | -$6.6M | -$3.35M | -$597K | -$300K | -$231.95M | -$309K | $0 |
| Net Cash from Investing | -$16.87M | $260.06M | -$10.23M | $193.25M | -$271.74M | -$8.74M | -$3.91M |
| Financing Activities | |||||||
| Debt Repaid | $8.43M | $4.44M | $766K | $90K | $12.8M | -$6.32M | -$705K |
| Common Stock Issuance | $532.96M | $300.42M | $128.09M | $143.71M | $462.9M | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$3M | $8.14M | $12.81M | $10.72M | $8.44M | $681K | -$210K |
| Net Cash from Financing | $521.53M | $304.12M | $140.13M | $154.34M | $458.54M | $246.13M | $120.41M |
| Forex Effect | $18.04M | -$3.41M | $188K | -$307K | $0 | $0 | $0 |
| Net Change in Cash | $150.9M | $201.6M | -$157.69M | $263.76M | $28.18M | $192M | $59.46M |
| Supplementary Data | |||||||
| Operating Cash Flow | -$371.81M | -$359.17M | -$287.78M | -$83.52M | -$158.61M | -$45.4M | -$57.04M |
| Capital Expenditure | -$6.47M | -$13.7M | -$11.96M | -$37.36M | -$39.8M | -$6.74M | -$3.91M |
| Free Cash Flow | -$378.28M | -$372.87M | -$300.33M | -$120.88M | -$198.41M | -$52.13M | -$60.95M |
| Cash at Beginning | $603.02M | $401.43M | $559.11M | $295.35M | $267.17M | $75.17M | $15.71M |
| Cash at End | $753.92M | $603.02M | $401.43M | $559.11M | $295.35M | $267.17M | $75.17M |